Opportunities Preloader

Please Wait.....

Report

India Breast Cancer Treatment Market Assessment, By Type [Ductal Carcinoma In Situ, Invasive Ductal Carcinoma, Lobular Carcinoma In Situ, Invasive Lobular Cancer, Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Breast Cancer During Pregnancy, Others], By Treatment Type [Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy, Others], By End-user [Cancer Research Institutes, Hospitals, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, FY2019-FY2033F

Market Report I 2025-06-16 I 124 Pages I Market Xcel - Markets and Data

India breast cancer treatment market is projected to witness a CAGR of 11.17% during the forecast period FY2026-FY2033, growing from USD 505.78 million in FY2025 to USD 1179.66 million in FY2033. The market's growth is augmented by the rising cases of breast cancer in the country, increasing efforts of research organizations to introduce advanced therapeutic solutions to combat breast cancer, and novel launches by leading players of the market. According to the Global Cancer Observatory, IARC-WHO, 2022, 98,337 deaths occurred due to breast cancer among females in 2022 in India.
The accessibility of breast cancer treatment is increasing across India due to the rising government initiatives, focus on improving healthcare infrastructure, and growing awareness about the condition. Advancements in medical technology and the introduction of innovative therapies, including targeted therapies, immunotherapies, and antibody-drug conjugates, are broadening the range of effective treatment options available in India. Additionally, the establishment of specialized cancer centers and improved diagnostic facilities are ensuring better disease management and positively influencing the market's expansion. Meanwhile, late-stage diagnosis in several cases, high costs of treatment, and lack of oncologists in the country pose challenges to the market's growth.
Increasing Efforts to Improve Breast Cancer Diagnosis Boosts Market Growth
Rising efforts to ensure early detection of breast cancer across the country are propelling the market's expansion as they are allowing the identification of cases at more treatable stages, augmenting the demand for treatment services. For instance, in November 2024, a team of oncologists under the Cancer Mukt Bharat campaign launched India's first 24x7 free Pink Cancer Helpline for promoting early detection of breast cancer. The helpline offers guidance via video and phone consultations, including preventive advice and self-examination instructions at no cost. Such initiatives promote awareness about breast cancer, reduce delays, and improve patient access to diagnostic technologies, in turn propelling the expansion of the market.
Increasing Research Efforts of Educational Organizations Support Market Expansion
Rising research efforts by educational organizations are fostering innovation, improving early detection of breast cancer, and enhancing patient outcomes. Institutions like the Cancer Research Institute at the Himalayan Institute of Medical Sciences has launched specialized clinics, including India's first Young Breast Cancer Clinic, to address the unique requirements of younger patients. Such efforts provide tailored care, promote targeted research, and set new benchmarks for breast cancer treatment and awareness.
Additionally, increasing research efforts are allowing institutes to receive approvals and patents, further encouraging different organizations to continue on with their research efforts. For instance, in February 2025, researchers from IIT Madras successfully developed and patented a next generation drug delivery system for treating breast cancer. The patented technology encapsulates anti-cancer drugs in the nanoparticles that directly target cancer cells, reducing side effects and minimizing damage to healthy tissues.
Development of New Breast Cancer Therapies is Driving the Market's Growth
The growing efforts of pharmaceutical companies and research organizations to boost the introduction of innovative breast cancer therapies in India is positively influencing the market's expansion. The availability of novel treatment solutions allows medical professionals to address the critical unmet requirements of the patient population and ensures that patients who previously had limited treatment options available have access to advanced therapies.
Research institutions across India are focusing on developing advanced therapies to improve drug delivery systems in order to combat the rising cases of breast cancer in the country. For instance, in January 2025, researchers from Institute Kolkata and IIT Guwahati developed an innovative injectable hydrogel for targeted breast cancer therapy. The hydrogel releases anti-cancer drugs in a controlled manner. The hydrogel reduces damage to healthy cells and minimizes systemic side effects by ensuring the delivery of chemotherapy drugs directly in the tumor sites.
Hospitals Holds Major Market Share
Hospital account for a significant share of the market as they have access to advanced therapeutic solutions and diagnostic technologies, provide multidisciplinary care, and a comprehensive infrastructure. Additionally, hospitals are better equipped to participate in clinical trials and invest in new technologies, enhancing treatment outcomes. Hospitals also act as key locations for screening programs and cancer awareness, improving the rate of diagnosis and thus treatment uptake. Moreover, a rising number of cancer hospitals are being constructed across the country to ensure that the patient population is provided with the required treatment solutions, thus bolstering the market's demand. For instance, in December 2024, the newly built Dr Sampat Kumar S. Shivangi Cancer Hospital was inaugurated in Karnataka. Such efforts are increasing the availability of advanced cancer care and improving diagnosis rates and treatment outcomes in underserved regions.
Impact of the U.S. Tariff on India Breast Cancer Treatment Market
Pharmaceutical exports have been exempted from the recent tariffs, however, the medical device industry, which is integral for early detection and treatment of cancer, is expected to face substantial challenges. Healthcare professionals might face challenges in procuring advanced equipment, hindering the diagnostic process, which is particularly crucial for ensuring effective treatment of breast cancer.
Additionally, the tariffs are going to impact Indian medical device manufacturers that export their products to the United States and result in decreased revenues, potentially limiting their resources for research and development activities, constraining the availability of novel diagnostic and therapeutic solutions.
Key Players Landscape and Outlook
The key players of the market are focusing on launching new drugs to aid the patient population in combating the disease and expanding their presence in the market. For instance, in January 2024, AstraZeneca Pharma India Limited launched Trastuzumab deruxtecan in India for treating adults with metastatic or unresectable HER2 positive breast cancer who have already received an anti-HER2 regimen. The introduction of this drug is seen as a major advancement, providing a transformative option for patients with aggressive breast cancer. Such launches address the critical unmet requirements of the patients by expanding the available treatment options.

1. Project Scope and Definitions
2. Research Methodology
3. Impact of the U.S. Tariff on India Breast Cancer Treatment Market
4. Executive Summary
5. India Breast Cancer Treatment Market Outlook, FY2019-FY2033F
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Type
5.2.1.1. Ductal Carcinoma In Situ (DCIS)
5.2.1.2. Invasive Ductal Carcinoma (IDC)
5.2.1.3. Lobular Carcinoma In Situ (LCIS)
5.2.1.4. Invasive Lobular Cancer (ILC)
5.2.1.5. Triple Negative Breast Cancer
5.2.1.6. Inflammatory Breast Cancer (IBC)
5.2.1.7. Metastatic Breast Cancer
5.2.1.8. Breast Cancer During Pregnancy
5.2.1.9. Other Types
5.2.2. By Treatment Type
5.2.2.1. Surgery
5.2.2.2. Radiation Therapy
5.2.2.3. Chemotherapy
5.2.2.4. Hormonal Therapy
5.2.2.4.1. Selective Estrogen Receptor Modulators
5.2.2.4.2. Aromatase Inhibitors
5.2.2.4.3. Estrogen Receptor Downregulators
5.2.2.5. Targeted Therapy
5.2.2.5.1. Abemaciclib
5.2.2.5.2. Adotrastuzumab Emtansine
5.2.2.5.3. Everolimus
5.2.2.5.4. Trastuzumab
5.2.2.5.5. Ribociclib
5.2.2.5.6. Palbocicib
5.2.2.5.7. Pertuzumab
5.2.2.5.8. Olaparib
5.2.2.5.9. Others
5.2.2.6. Immunotherapy
5.2.2.7. Others
5.2.3. By End-user
5.2.3.1. Cancer Research Institutes
5.2.3.2. Hospitals
5.2.3.3. Ambulatory Surgical Centers
5.2.3.4. Others
5.2.4. By Region
5.2.4.1. North
5.2.4.2. South
5.2.4.3. East
5.2.4.4. West & Central
5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
5.3. Market Map Analysis, FY2025
5.3.1. By Type
5.3.2. By Treatment Type
5.3.3. By End-user
5.3.4. By Region
6. Demand Supply Analysis
7. Value Chain Analysis
8. Porter's Five Forces Analysis
9. PESTLE Analysis
10. Pricing Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Regulatory Approvals
13.2. Clinical Trials
14. Patent Landscape
15. Case Studies
16. Competitive Landscape
16.1. Competition Matrix of Top 5 Market Leaders
16.2. SWOT Analysis for Top 5 Players
16.3. Key Players Landscape for Top 10 Market Players
16.3.1. Novartis Healthcare Private Limited
16.3.1.1. Company Details
16.3.1.2. Key Management Personnel
16.3.1.3. Products and Services
16.3.1.4. Financials (As Reported)
16.3.1.5. Key Market Focus and Geographical Presence
16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
16.3.2. Pfizer India Inc.
16.3.3. Eisai Pharmaceuticals India Pvt. Ltd.
16.3.4. Merck & Co., Inc.
16.3.5. Kyowa Kirin Co., Ltd.
16.3.6. Eli Lilly and Company (India) Pvt. Ltd.
16.3.7. Bristol Myers Squibb India Pvt Ltd
16.3.8. AstraZeneca Pharma India Limited
16.3.9. Sanofi India Limited
16.3.10. Daiichi Sankyo Company, Limited
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
17. Strategic Recommendations
18. About Us and Disclaimer

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3500.00
  • $4700.00
  • $7200.00
  • ADD TO BASKET
  • BUY NOW